Skip to content Skip to sidebar Skip to footer

Newsletter

Charlie Youlden

Charlie is an Associate Equity Research Analyst covering ASX small caps across technology, mining and industrials.

His investing journey began in 2020 with large-cap US technology stocks, before he went on to complete a Commerce degree in Finance and Marketing at UTS, the Wall Street Prep Financial Modelling course, and Columbia Business School’s Value Investing course.

Charlie’s goal is to make investing clear, digestible and genuinely useful for everyday retail investors, helping them make better decisions with more confidence.

666 articles published

Market news

How Long-Term Returns Are Shaped by Financial Cycles

Investors who think the present will last forever are often humbled by markets. Easy money eras seem to last forever—until they don't. While downturns provide the impression that opportunity has permanently disappeared, booms persuade investors that risk has disappeared. However, history demonstrates that neither extreme is sustainable. The underlying rhythm of financial cycles is what endures.…

ByCharlie YouldenFebruary 20, 20260Comments

Tech Stocks Technology

Sonic Healthcare (ASX:SHL) Still Compounding, Integration Is the Near Term Drag

The Quality Compounder, With a Margin Reset Under the Hood Sonic Healthcare is one of the ASX 200’s higher quality compounders, and its half year result shows the earnings base is still expanding, even if margin and mix are doing some heavy lifting behind the scenes. Here is a quick snapshot of the standout metrics: EBITDA of…

ByCharlie YouldenFebruary 19, 20260Comments

Tech Stocks Technology

Zip Co (ASX:ZIP) Down 31% on a Strong Half, What Did the Market See?

Zip Co US Growth Story Is Working, Investors Fear the Mix Shift There was a lot of panic selling in Zip Co at the open today, with the share price falling to around $1.90, down 31% after the release of its 1H FY26 result. What makes the reaction interesting is that Zip actually delivered a strong half,…

ByCharlie YouldenFebruary 19, 20260Comments

Tech Stocks Technology

TechnologyOne (ASX:TNE) Defying the AI Doom Trade With 18% to 20% PBT Growth

SaaS Plus AI Momentum Drives a FY26 Upgrade TechnologyOne is defying the market’s AI shock narrative. For readers who came across our article on AI and SaaS disruption, you will remember our core point: we believe the market has overstated the impact AI will have on high quality SaaS businesses, especially those with embedded workflows, sticky…

ByCharlie YouldenFebruary 18, 20260Comments

Tech Stocks Technology

Hansen Technologies (ASX:HSN) Cash Acceleration Is the Story in 1H FY26

Hansen Technologies 7% Sales Growth, 46% EBITDA Growth, Execution Tightens Hansen Technologies delivered steady revenue growth, but a sharp uplift in profit, which triggered a re rating this morning as the market reacted to cash acceleration in the latest half. What we like here is that Hansen is starting to demonstrate improving efficiency. You can see…

ByCharlie YouldenFebruary 18, 20260Comments

Consumer Retail Tech Stocks Technology

JB Hi-Fi Earnings: Good Results and AI Optimism Spark a 12% Re Rate!

JB Hi-Fi Earnings: The Market Reprices Quality And AI Exposure JB Hi-Fi has seen a strong re rate over the past week, up around 12% following a solid 1H FY26 result which showed it could be an AI winner. At a headline level, its 1H26 result was clean and showed good growth. Group sales came in at…

ByCharlie YouldenFebruary 17, 20260Comments

Tech Stocks Technology

Nanoveu (ASX:NVU) NTU Drone Swarm IP, GPS Free Navigation Goes on Trial

Testing GPS Free Swarm Tech With NTU Nanoveu today announced it has entered an exclusive evaluation licence with Nanyang Technological University covering four inventions focused on GPS free localisation and coordination methods for drone swarm navigation. For investors, the key point is that this is an evaluation first, with an option to convert into exclusive rights…

ByCharlie YouldenFebruary 17, 20260Comments

Healthcare Stocks

Botanix (ASX:BOT) Down 40% on a $45m Raise, Dilution Shock Hits Hard

A Steep Discount, A Big Dilution, A New Valuation Anchor Botanix started the session with a sharp sell off, falling as much as 40% and printing its lowest level in roughly three years, sliding back to around 6.9c. The key driver was the company’s announcement that it is targeting a A$45m capital raising. The raise is led…

ByCharlie YouldenFebruary 17, 20260Comments

Healthcare Stocks Tech Stocks Technology

Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors

Australian Clinical Labs fell 10% today after revenue went slightly backwards, even though underlying profit improved. The key nuance is that management deliberately walked away from low margin collection centres and contracts. That decision can pull revenue down in the short term, but it should lift margins and improve the quality of earnings over time. The sharper…

ByCharlie YouldenFebruary 16, 20260Comments

Market news

Eden Innovations (ASX:EDE) Up 30% on a Debt Free Reset, But Dilution Is the Price

$2.2m Loan Converts, Balance Sheet Clears, Shares Reprice Eden Innovations surged 30% today to 24.5c after announcing it has converted a $2.2m loan into equity for a strategic investor. On top of that, the company said all remaining shareholder loans and unpaid director fees will also be settled in shares, which would leave it debt free. The…

ByCharlie YouldenFebruary 16, 20260Comments